On September 19, 2025, the FDA granted subcutaneous pembrolizumab approval. This approval includes berahyaluronidase alfa-pmph (Keytruda Qlex). It is the first subcutaneous immune checkpoint inhibitor for solid tumor indications in adults and pedi...